Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalmefene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 9/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalmefene SCHEMBL14124638 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL4556466 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18827079 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12646154 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18457569 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL35230 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18160036 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12945213 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12566030 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12233286 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10005791-B2 | O-demethylating process of methoxy substituted morphinan-6-one derivatives | NORAMCO GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-10005791-B2 | O-demethylating process of methoxy substituted morphinan-6-one derivatives | NORAMCO GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-9969746-B2 | Opioid compounds and their uses | THE UNIVERSITY OF BATH (GB) | 2018-05-15 | — | — | US | disclosed |
| EP-3129383-B1 | O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES | CILAG AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9757372-B2 | Toll-like receptor 4 antagonists and use in autoimmune liver diseases | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2017-09-12 | — | — | US | disclosed |
| US-20170022211-A1 | O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES | CILAG AG (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20170022211-A1 | O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES | CILAG AG (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2015155181-A1 | O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES | CILAG AG (CH) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022211-A1 | O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES | TET2, ALKBH5, METTL3 | OPRD1 251/4885OPRM1 101/4885OPRK1 404/4885 |
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | OPRD1 4/4885OPRM1 1/4885OPRK1 2/4885 |
| US-10005791-B2 | O-demethylating process of methoxy substituted morphinan-6-one derivatives | TET2, ALKBH5, METTL3 | OPRD1 277/4885OPRM1 111/4885OPRK1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.